Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Patient Dies After Receiving Sarepta’s Gene Therapy
Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...
BioPharma Dive5h
Cell, gene therapy makers lose a champion at FDA with exit of Peter Marks
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
A recent gene therapy death shines a light on AAV safety
The death of a 16-year-old boy taking a gene therapy this month dealt a fresh blow to the Duchenne muscular dystrophy ...
Teenager who received Elevidys, Sarepta’s Duchenne gene therapy, dies
Elevidys was approved after intense debate at the FDA, as officials and reviewers disagreed over how strong the evidence was ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare musc ...
GEN - Genetic Engineering and Biotechnology News3d
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates
Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...
StockStory.org on MSN9h
Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 10.8% in the afternoon session after RBC analyst Brian ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the ...
Sarepta’s Gene Therapy Under Scrutiny After Patient Death
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, ...
Vaccine, gene therapy makers fall after Peter Marks resignation
Novavax (NVAX), and BioNTech (BNTX) (BTNX), and gene therapy developers, including Sarepta (SRPT), Solid Biosciences (SLDB), Taysha Gene Therapies (TSHA), Capricor Therapeutics (CAPR), and Crispr ...
BioPharma Dive13d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...